1. MAPK/ERK Pathway Autophagy Metabolic Enzyme/Protease Anti-infection
  2. MAP3K Autophagy Endogenous Metabolite HIV
  3. Oleanolic acid

Oleanolic acid  (Synonyms: Oleanic acid; Caryophyllin)

Cat. No.: HY-N0156 Purity: ≥98.0%
Handling Instructions Technical Support

Oleanolic acid (Caryophyllin) is a natural compound from plants with anti-tumor activities.

For research use only. We do not sell to patients.

Oleanolic acid Chemical Structure

Oleanolic acid Chemical Structure

CAS No. : 508-02-1

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
100 mg In-stock
500 mg In-stock
1 g   Get quote  
5 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 11 publication(s) in Google Scholar

Other Forms of Oleanolic acid:

Top Publications Citing Use of Products

View All MAP3K Isoform Specific Products:

View All HIV Isoform Specific Products:

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Oleanolic acid (Caryophyllin) is a natural compound from plants with anti-tumor activities.

IC50 & Target

ASK1

 

Cellular Effect
Cell Line Type Value Description References
4T1 IC50
514.1 μM
Compound: 3; OA
Cytotoxicity activity against mouse 4T1 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity activity against mouse 4T1 cells assessed as cell growth inhibition after 48 hrs by MTT assay
[PMID: 30433783]
518A2 EC50
> 30 μM
Compound: 2
Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay
Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay
[PMID: 28033541]
518A2 EC50
> 30 μM
Compound: OA
Cytotoxicity against human 518A2 cells assessed as cell survival after 96 hrs by SRB assay
Cytotoxicity against human 518A2 cells assessed as cell survival after 96 hrs by SRB assay
[PMID: 26177446]
518A2 EC50
> 30 μM
Compound: OA
Cytotoxicity against human 518A2 cells after 96 hrs by sulforhodamine B assay
Cytotoxicity against human 518A2 cells after 96 hrs by sulforhodamine B assay
[PMID: 30278332]
518A2 IC50
> 60 μM
Compound: OA
Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay
Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay
[PMID: 24361521]
518A2 EC50
61.3 μM
Compound: OA
Cytotoxicity against human 518A2 cells after 96 hrs by sulforhodamine-B assay
Cytotoxicity against human 518A2 cells after 96 hrs by sulforhodamine-B assay
[PMID: 29529499]
518A2 EC50
64.3 μM
Compound: OA
Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay
Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay
[PMID: 26750249]
518A2 EC50
64.3 μM
Compound: 1; OA
Cytotoxicity against human 518A2 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
Cytotoxicity against human 518A2 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
[PMID: 27149037]
8505C EC50
> 30 μM
Compound: 2
Cytotoxicity against human 8505C cells after 96 hrs by SRB assay
Cytotoxicity against human 8505C cells after 96 hrs by SRB assay
[PMID: 28033541]
8505C EC50
> 30 μM
Compound: OA
Cytotoxicity against human 8505C cells assessed as cell survival after 96 hrs by SRB assay
Cytotoxicity against human 8505C cells assessed as cell survival after 96 hrs by SRB assay
[PMID: 26177446]
8505C EC50
> 30 μM
Compound: OA
Cytotoxicity against human 8505C cells after 96 hrs by sulforhodamine B assay
Cytotoxicity against human 8505C cells after 96 hrs by sulforhodamine B assay
[PMID: 30278332]
8505C IC50
> 60 μM
Compound: OA
Cytotoxicity against human 8505C cells after 96 hrs by SRB assay
Cytotoxicity against human 8505C cells after 96 hrs by SRB assay
[PMID: 24361521]
A2780 EC50
> 30 μM
Compound: OA
Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay
Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay
[PMID: 31718946]
A2780 EC50
> 30 μM
Compound: OA
Cytotoxicity against human A2780 cells after 96 hrs by sulforhodamine B assay
Cytotoxicity against human A2780 cells after 96 hrs by sulforhodamine B assay
[PMID: 30278332]
A2780 EC50
14 μM
Compound: 2
Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
[PMID: 28033541]
A2780 EC50
14 μM
Compound: OA
Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
[PMID: 26750249]
A2780 IC50
14 μM
Compound: OA
Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
[PMID: 24361521]
A2780 EC50
14 μM
Compound: 1; OA
Cytotoxicity against human A2780 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
Cytotoxicity against human A2780 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
[PMID: 27149037]
A2780 EC50
58.2 μM
Compound: OA
Cytotoxicity against human A2780 cells after 96 hrs by sulforhodamine-B assay
Cytotoxicity against human A2780 cells after 96 hrs by sulforhodamine-B assay
[PMID: 29529499]
A-375 IC50
328.8 μM
Compound: 3; OA
Cytotoxicity activity against human A375 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity activity against human A375 cells assessed as cell growth inhibition after 48 hrs by MTT assay
[PMID: 30433783]
A549 IC50
> 100 μM
Compound: OA
Antiproliferative activity against human A549 cells after 48 hrs by CCK-8 assay
Antiproliferative activity against human A549 cells after 48 hrs by CCK-8 assay
[PMID: 26343825]
A549 IC50
> 100 μM
Compound: 1, oleanolic acid
Cytotoxicity against human A549 cells after 1 hr by MTT assay
Cytotoxicity against human A549 cells after 1 hr by MTT assay
[PMID: 18343122]
A549 GI50
> 100 μM
Compound: 27
Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay
[PMID: 32345458]
A549 IC50
> 200 μM
Compound: 4
Cell membrane permeabilization in human A549 cells assessed as drug level causing decrease in calcein fluorescence
Cell membrane permeabilization in human A549 cells assessed as drug level causing decrease in calcein fluorescence
[PMID: 19200744]
A549 EC50
> 30 μM
Compound: 2
Cytotoxicity against human A549 cells after 96 hrs by SRB assay
Cytotoxicity against human A549 cells after 96 hrs by SRB assay
[PMID: 28033541]
A549 EC50
> 30 μM
Compound: OA
Cytotoxicity against human A549 cells assessed as cell survival after 96 hrs by SRB assay
Cytotoxicity against human A549 cells assessed as cell survival after 96 hrs by SRB assay
[PMID: 26177446]
A549 EC50
> 30 μM
Compound: OA
Cytotoxicity against human A549 cells after 96 hrs by sulforhodamine B assay
Cytotoxicity against human A549 cells after 96 hrs by sulforhodamine B assay
[PMID: 30278332]
A549 IC50
0.39 μM
Compound: 1, OA
Cytotoxicity against human A549 cells by MTT assay
Cytotoxicity against human A549 cells by MTT assay
[PMID: 23434227]
A549 IC50
16.29 μM
Compound: 1
Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
10.1039/C6MD00061D
A549 IC50
19.94 μM
Compound: OA
Cytotoxicity against human A549 cells assessed as cell viability after 72 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as cell viability after 72 hrs by MTT assay
[PMID: 23992864]
A549 IC50
209 μM
Compound: 10
Cytotoxicity against human A549 cells assessed as cell viability after 24 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as cell viability after 24 hrs by MTT assay
[PMID: 15730243]
A549 IC50
27 μM
Compound: 4
Cytotoxicity against human A549 cells after 48 hrs by resazurin reduction test
Cytotoxicity against human A549 cells after 48 hrs by resazurin reduction test
[PMID: 19200744]
A549 IC50
41.65 μM
Compound: 1; OA
Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay
[PMID: 31673307]
A549 IC50
6.4 μM
Compound: OA
Antiproliferative activity against human A549 cells harbouring wild type EGFR incubated for 72 hrs by SRB assay
Antiproliferative activity against human A549 cells harbouring wild type EGFR incubated for 72 hrs by SRB assay
[PMID: 31718182]
A549 EC50
64.1 μM
Compound: OA
Cytotoxicity against human A549 cells after 96 hrs by sulforhodamine-B assay
Cytotoxicity against human A549 cells after 96 hrs by sulforhodamine-B assay
[PMID: 29529499]
A549 IC50
64.26 μM
Compound: 3; OA
Cytotoxicity activity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity activity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay
[PMID: 30433783]
A549 EC50
72.3 μM
Compound: OA
Cytotoxicity against human A549 cells after 96 hrs by SRB assay
Cytotoxicity against human A549 cells after 96 hrs by SRB assay
[PMID: 26750249]
A549 IC50
72.3 μM
Compound: OA
Cytotoxicity against human A549 cells after 96 hrs by SRB assay
Cytotoxicity against human A549 cells after 96 hrs by SRB assay
[PMID: 24361521]
A549 EC50
72.3 μM
Compound: 1; OA
Cytotoxicity against human A549 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
Cytotoxicity against human A549 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
[PMID: 27149037]
A549 IC50
81.4 μM
Compound: OA
Cytotoxicity against human A549 cells after 48 hrs by CCK-8 assay
Cytotoxicity against human A549 cells after 48 hrs by CCK-8 assay
[PMID: 24422538]
A549 IC50
96.2 μM
Compound: 10
Antiinflammatory activity against human A549 cells assessed as inhibition of IL-1-alpha-induced ICAM1 expression treated after 1 hr before IL1alpha challenge
Antiinflammatory activity against human A549 cells assessed as inhibition of IL-1-alpha-induced ICAM1 expression treated after 1 hr before IL1alpha challenge
[PMID: 15730243]
A549/TR IC50
> 200 μM
Compound: 1; OA
Cytotoxicity against human A549/T cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human A549/T cells assessed as cell growth inhibition after 48 hrs by MTT assay
[PMID: 31673307]
B16 IC50
4.8 μM
Compound: 18
Growth inhibition of mouse B16 2F2 cells after 3 days
Growth inhibition of mouse B16 2F2 cells after 3 days
[PMID: 12027734]
B16-F10 IC50
106.4 μM
Compound: OA
Cytotoxicity against mouse B16-F10 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Cytotoxicity against mouse B16-F10 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
[PMID: 36542806]
B16-F10 IC50
106.4 μM
Compound: I, Oleanolic acid
Growth inhibition of mouse B16F10 cells after 72 hrs by MTT assay
Growth inhibition of mouse B16F10 cells after 72 hrs by MTT assay
[PMID: 29471121]
B16-F10 IC50
106.4 μM
Compound: I; OA; Oleanolic and
Cytotoxicity against mouse B16F10 cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against mouse B16F10 cells assessed as growth inhibition after 72 hrs by MTT assay
[PMID: 27128174]
B16-F10 IC50
106.4 μM
Compound: 1, OA, Oleanolic acid
Cytotoxicity against mouse B16F10 cells after 72 hrs by MTT assay
Cytotoxicity against mouse B16F10 cells after 72 hrs by MTT assay
[PMID: 24480359]
B16-F10 IC50
388.3 μM
Compound: 3; OA
Cytotoxicity activity against mouse B16F10 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity activity against mouse B16F10 cells assessed as cell growth inhibition after 48 hrs by MTT assay
[PMID: 30433783]
Bel-7402 IC50
59.94 μM
Compound: 1; OA
Cytotoxicity against human Bel7402 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human Bel7402 cells assessed as cell growth inhibition after 48 hrs by MTT assay
[PMID: 31673307]
Bel7402/5-FU IC50
> 200 μM
Compound: 1; OA
Cytotoxicity against human Bel7402/5-FU cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human Bel7402/5-FU cells assessed as cell growth inhibition after 48 hrs by MTT assay
[PMID: 31673307]
BEL-7404 tumor cell line IC50
57.89 μM
Compound: 1, OA
Cytotoxicity against human Bel7404 cells after 72 hrs by MTT assay
Cytotoxicity against human Bel7404 cells after 72 hrs by MTT assay
10.1039/C2MD20051A
BGC-823 IC50
2.59 μM
Compound: 1, OA
Cytotoxicity against human BGC823 cells by MTT assay
Cytotoxicity against human BGC823 cells by MTT assay
[PMID: 23434227]
BGC-823 IC50
23.74 μM
Compound: 1
Cytotoxicity against human BGC823 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
Cytotoxicity against human BGC823 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
10.1039/C6MD00061D
BMDC IC50
> 50 μM
Compound: 22
Antiinflammatory activity in C57BL/6 mouse BMDCs assessed as inhibition of LPS-stimulated IL-12p40 production treated 1 hr before LPS challenge measured 18 hrs post stimulation by ELISA
Antiinflammatory activity in C57BL/6 mouse BMDCs assessed as inhibition of LPS-stimulated IL-12p40 production treated 1 hr before LPS challenge measured 18 hrs post stimulation by ELISA
[PMID: 23484668]
BMDC IC50
> 50 μM
Compound: 22
Antiinflammatory activity in C57BL/6 mouse BMDCs assessed as inhibition of LPS-stimulated IL12 production treated 1 hr before LPS challenge measured 18 hrs post stimulation by ELISA
Antiinflammatory activity in C57BL/6 mouse BMDCs assessed as inhibition of LPS-stimulated IL12 production treated 1 hr before LPS challenge measured 18 hrs post stimulation by ELISA
[PMID: 23484668]
BMDC IC50
> 50 μM
Compound: 22
Antiinflammatory activity in C57BL/6 mouse BMDCs assessed as inhibition of LPS-stimulated TNF-alpha production treated 1 hr before LPS challenge measured 18 hrs post stimulation by ELISA
Antiinflammatory activity in C57BL/6 mouse BMDCs assessed as inhibition of LPS-stimulated TNF-alpha production treated 1 hr before LPS challenge measured 18 hrs post stimulation by ELISA
[PMID: 23484668]
CAPAN-1 IC50
50.1 μM
Compound: OA
Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay
Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay
[PMID: 34352711]
CHO EC50
2.25 μM
Compound: 2
Agonist activity at TGR5 expressed in CHO cells by CRE-driven luciferase reporter gene assay
Agonist activity at TGR5 expressed in CHO cells by CRE-driven luciferase reporter gene assay
[PMID: 19911773]
COLO 205 IC50
> 10 μM
Compound: 6
Cytotoxicity against human COLO205 cells after 24 hrs by MTT assay
Cytotoxicity against human COLO205 cells after 24 hrs by MTT assay
[PMID: 30199257]
COLO 320 IC50
> 10 μM
Compound: 6
Cytotoxicity against human COLO320 cells after 24 hrs by MTT assay
Cytotoxicity against human COLO320 cells after 24 hrs by MTT assay
[PMID: 30199257]
COS-1 EC50
0 μM
Compound: 2
Agonist activity at human FXR expressed in COS1 cells by luciferase reporter gene assay
Agonist activity at human FXR expressed in COS1 cells by luciferase reporter gene assay
[PMID: 19911773]
DLD-1 IC50
> 100 μM
Compound: 4
Cytotoxicity against human DLD1 cells after 48 hrs by resazurin reduction test
Cytotoxicity against human DLD1 cells after 48 hrs by resazurin reduction test
[PMID: 19200744]
DLD-1 IC50
> 200 μM
Compound: 4
Cell membrane permeabilization in human DLD1 cells assessed as drug level causing decrease in calcein fluorescence
Cell membrane permeabilization in human DLD1 cells assessed as drug level causing decrease in calcein fluorescence
[PMID: 19200744]
DU-145 IC50
124 μM
Compound: 10
Antiproliferative activity in human DU145 cells by sulforhodamine B assay
Antiproliferative activity in human DU145 cells by sulforhodamine B assay
[PMID: 29120172]
DU-145 CC50
65.6 μM
Compound: 10
Cytotoxic activity in human DU145 cells by sulforhodamine B assay
Cytotoxic activity in human DU145 cells by sulforhodamine B assay
[PMID: 29120172]
FaDu EC50
> 30 μM
Compound: OA
Cytotoxicity against human FADU cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay
Cytotoxicity against human FADU cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay
[PMID: 31718946]
FaDu EC50
66.7 μM
Compound: OA
Cytotoxicity against human FADU cells after 96 hrs by sulforhodamine-B assay
Cytotoxicity against human FADU cells after 96 hrs by sulforhodamine-B assay
[PMID: 29529499]
FaDu EC50
75.4 μM
Compound: OA
Cytotoxicity against human FADU cells after 96 hrs by SRB assay
Cytotoxicity against human FADU cells after 96 hrs by SRB assay
[PMID: 26750249]
FaDu EC50
75.4 μM
Compound: 1; OA
Cytotoxicity against human FADU cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
Cytotoxicity against human FADU cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
[PMID: 27149037]
H9 EC50
1.7 μg/mL
Compound: 1
Cytotoxicity against mock-infected human H9 cells after 4 days
Cytotoxicity against mock-infected human H9 cells after 4 days
[PMID: 9748372]
H9 IC50
21.8 μg/mL
Compound: 1
Antiviral activity against HIV1 3B in human H9 cells after 4 days by p24 antigen ELISA
Antiviral activity against HIV1 3B in human H9 cells after 4 days by p24 antigen ELISA
[PMID: 9748372]
H9 IC50
47.8 μM
Compound: 3
Antiviral activity against HIV1 3B isolate replication in human H9 cells assessed as decrease in viral p24 level after 4 days
Antiviral activity against HIV1 3B isolate replication in human H9 cells assessed as decrease in viral p24 level after 4 days
[PMID: 11141100]
HCT-116 GI50
> 100 μM
Compound: 27
Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay
[PMID: 32345458]
HCT-116 IC50
> 150 μM
Compound: OA
Cytotoxicity against human HCT116 cells after 48 hrs by CCK-8 assay
Cytotoxicity against human HCT116 cells after 48 hrs by CCK-8 assay
[PMID: 24422538]
HCT-116 IC50
32.4 μM
Compound: OA
Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay
Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay
[PMID: 34352711]
HCT-116 IC50
4.8 μM
Compound: Oleanolic acid
Cytotoxicity against human HCT116 cells by MTT assay
Cytotoxicity against human HCT116 cells by MTT assay
[PMID: 20951582]
HEK293 CC50
> 500 μM
Compound: 10
Cytotoxic activity in HEK293 cells by sulforhodamine B assay
Cytotoxic activity in HEK293 cells by sulforhodamine B assay
[PMID: 29120172]
HEK293 IC50
> 500 μM
Compound: 10
Antiproliferative activity in HEK293 cells by sulforhodamine B assay
Antiproliferative activity in HEK293 cells by sulforhodamine B assay
[PMID: 29120172]
HEK293 IC50
329 μM
Compound: 9
Cytotoxicity against human HEK293 cells assessed as cell viability after 24 hrs by cell titer-blue assay
Cytotoxicity against human HEK293 cells assessed as cell viability after 24 hrs by cell titer-blue assay
[PMID: 26473275]
HEL EC50
> 1 μM
Compound: OA
Antiproliferative activity against human HEL cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
Antiproliferative activity against human HEL cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
[PMID: 33569941]
HeLa IC50
> 100 μM
Compound: OA
Antiproliferative activity against human HeLa cells after 48 hrs by CCK-8 assay
Antiproliferative activity against human HeLa cells after 48 hrs by CCK-8 assay
[PMID: 26343825]
HeLa IC50
> 100 μM
Compound: 1, Oleanolic acid
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
[PMID: 24487188]
HeLa CC50
> 500 μM
Compound: 10
Cytotoxic activity in human HeLa cells by sulforhodamine B assay
Cytotoxic activity in human HeLa cells by sulforhodamine B assay
[PMID: 29120172]
HeLa IC50
204.5 μM
Compound: 10
Antiproliferative activity in human HeLa cells by sulforhodamine B assay
Antiproliferative activity in human HeLa cells by sulforhodamine B assay
[PMID: 29120172]
HeLa IC50
31.38 μM
Compound: OA
Cytotoxicity against human HeLa cells assessed as cell viability after 72 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as cell viability after 72 hrs by MTT assay
[PMID: 23992864]
HeLa IC50
4 μM
Compound: 1
Inhibition of N-terminal 6His-tagged human AKR1B10 overexpressed in human HeLa cells assessed as inhibition of [1-14C]farnesol reduction pretreated for 2 hrs before [1-14C]farnesol challenge measured after 6 hrs
Inhibition of N-terminal 6His-tagged human AKR1B10 overexpressed in human HeLa cells assessed as inhibition of [1-14C]farnesol reduction pretreated for 2 hrs before [1-14C]farnesol challenge measured after 6 hrs
[PMID: 21561086]
HEp-2 CC50
> 500 μM
Compound: 10
Cytotoxic activity in human Hep2 cells by sulforhodamine B assay
Cytotoxic activity in human Hep2 cells by sulforhodamine B assay
[PMID: 29120172]
HEp-2 IC50
> 500 μM
Compound: 10
Antiproliferative activity in human Hep2 cells by sulforhodamine B assay
Antiproliferative activity in human Hep2 cells by sulforhodamine B assay
[PMID: 29120172]
HepG2 IC50
> 10 μM
Compound: 16
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
[PMID: 27797185]
HepG2 IC50
> 100 μM
Compound: 11
Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by neutral red assay
Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by neutral red assay
[PMID: 28318944]
HepG2 IC50
14.72 μM
Compound: OA
Cytotoxicity against human HepG2 cells assessed as cell viability after 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as cell viability after 72 hrs by MTT assay
[PMID: 23992864]
HepG2 IC50
15.9 μM
Compound: 1
Cytotoxicity against human HepG2 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
10.1039/C6MD00061D
HepG2 IC50
165 μM
Compound: 10
Cytotoxicity against human Hep G2 cells after 48 hrs by WST-8 assay
Cytotoxicity against human Hep G2 cells after 48 hrs by WST-8 assay
[PMID: 15730243]
HepG2 IC50
211.8 μM
Compound: OA
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
[PMID: 36542806]
HepG2 IC50
211.8 μM
Compound: I, Oleanolic acid
Growth inhibition of human HepG2 cells after 72 hrs by MTT assay
Growth inhibition of human HepG2 cells after 72 hrs by MTT assay
[PMID: 29471121]
HepG2 IC50
211.8 μM
Compound: I; OA; Oleanolic and
Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by MTT assay
[PMID: 27128174]
HepG2 IC50
51.4 μM
Compound: OA
Cytotoxicity against human HepG2 cells after 48 hrs by CCK-8 assay
Cytotoxicity against human HepG2 cells after 48 hrs by CCK-8 assay
[PMID: 24422538]
HepG2 2.2.15 CC50
731.2 μM
Compound: D1; OA
Cytotoxicity against human HepG2.215 cells assessed as reduction in cell viability after 3 days by MTT assay
Cytotoxicity against human HepG2.215 cells assessed as reduction in cell viability after 3 days by MTT assay
[PMID: 29627260]
HL-60 IC50
> 30 μM
Compound: 1; OA
Cytotoxicity against human HL60 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human HL60 cells assessed as cell growth inhibition after 48 hrs by MTT assay
[PMID: 29133061]
HL-60 IC50
> 50 μg/mL
Compound: oleanolic acid
Cytotoxicity against human HL-60 cells after 72 hrs by MTT assay
Cytotoxicity against human HL-60 cells after 72 hrs by MTT assay
[PMID: 10514313]
HL-60 IC50
14.75 μM
Compound: 1; OA
Cytotoxicity in human HL60 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Cytotoxicity in human HL60 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
[PMID: 28754470]
HL-60 IC50
16.17 μM
Compound: OA
Cytotoxicity against human HL60 cells assessed as cell viability after 72 hrs by MTT assay
Cytotoxicity against human HL60 cells assessed as cell viability after 72 hrs by MTT assay
[PMID: 23992864]
HL-60 IC50
36.4 μM
Compound: OA
Antiproliferative activity against human HL-60 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis
Antiproliferative activity against human HL-60 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis
[PMID: 34352711]
HL-60 IC50
54.56 μM
Compound: 1, OA
Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
10.1039/C2MD20051A
HL-60 IC50
77.48 μM
Compound: Oleanolic acid
Cytotoxicity against human HL60 cells by MTT assay
Cytotoxicity against human HL60 cells by MTT assay
[PMID: 20951582]
HL60/ADR IC50
28.75 μM
Compound: 1; OA
Cytotoxicity in human HL60/ADR cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Cytotoxicity in human HL60/ADR cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
[PMID: 28754470]
HSC-T6 EC50
59.6 nM
Compound: 139
Antiproliferative activity against rat HSC-T6 cells assessed as reduction in cell proliferation measured after 48 hrs by MTT assay
Antiproliferative activity against rat HSC-T6 cells assessed as reduction in cell proliferation measured after 48 hrs by MTT assay
[PMID: 29353722]
HT-29 EC50
> 10 μM
Compound: 8
Anti-necroptotic activity in human HT-29 cells assessed as inhibition of TNFalpha/SM-164/Z-VAD-fmk (TSZ)-induced necroptosis by measuring increase in cell viability measured after 12 hrs by celltiter-glo luminescent cell viability assay
Anti-necroptotic activity in human HT-29 cells assessed as inhibition of TNFalpha/SM-164/Z-VAD-fmk (TSZ)-induced necroptosis by measuring increase in cell viability measured after 12 hrs by celltiter-glo luminescent cell viability assay
[PMID: 33248849]
HT-29 IC50
> 10 μM
Compound: 8
Inhibition of mitochondrial membrane potential in human HT-29 cells after 3 hrs by JC-1 staining based fluorescence assay
Inhibition of mitochondrial membrane potential in human HT-29 cells after 3 hrs by JC-1 staining based fluorescence assay
[PMID: 30057155]
HT-29 IC50
> 10 μM
Compound: 8
Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
[PMID: 30057155]
HT-29 IC50
> 100 μM
Compound: 1, Oleanolic acid
Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay
Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay
[PMID: 24487188]
HT-29 IC50
> 30 μM
Compound: 1; OA
Cytotoxicity against human HT-29 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human HT-29 cells assessed as cell growth inhibition after 48 hrs by MTT assay
[PMID: 29133061]
HT-29 EC50
> 30 μM
Compound: OA
Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay
Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay
[PMID: 31718946]
HT-29 EC50
> 30 μM
Compound: 2
Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay
Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay
[PMID: 28033541]
HT-29 EC50
> 30 μM
Compound: OA
Cytotoxicity against human HT-29 cells assessed as cell survival after 96 hrs by SRB assay
Cytotoxicity against human HT-29 cells assessed as cell survival after 96 hrs by SRB assay
[PMID: 26177446]
HT-29 EC50
> 30 μM
Compound: OA
Cytotoxicity against human HT-29 cells after 96 hrs by sulforhodamine B assay
Cytotoxicity against human HT-29 cells after 96 hrs by sulforhodamine B assay
[PMID: 30278332]
HT-29 EC50
38.8 μM
Compound: OA
Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay
Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay
[PMID: 26750249]
HT-29 IC50
38.8 μM
Compound: OA
Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay
Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay
[PMID: 24361521]
HT-29 EC50
38.8 μM
Compound: 1; OA
Cytotoxicity against human HT-29 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
Cytotoxicity against human HT-29 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
[PMID: 27149037]
HT-29 IC50
429.9 μM
Compound: OA
Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
[PMID: 36542806]
HT-29 IC50
429.9 μM
Compound: I, Oleanolic acid
Growth inhibition of human HT-29 cells after 72 hrs by MTT assay
Growth inhibition of human HT-29 cells after 72 hrs by MTT assay
[PMID: 29471121]
HT-29 IC50
429.9 μM
Compound: I; OA; Oleanolic and
Cytotoxicity against human HT-29 cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human HT-29 cells assessed as growth inhibition after 72 hrs by MTT assay
[PMID: 27128174]
HT-29 EC50
44.9 μM
Compound: OA
Cytotoxicity against human HT-29 cells after 96 hrs by sulforhodamine-B assay
Cytotoxicity against human HT-29 cells after 96 hrs by sulforhodamine-B assay
[PMID: 29529499]
J774 IC50
130.5 μM
Compound: 8
Cytotoxicity against mouse J774 cells by alamar blue assay
Cytotoxicity against mouse J774 cells by alamar blue assay
[PMID: 17637068]
J774.A1 IC50
35.2 μM
Compound: 1, Oleanolic acid
Inhibition of LPS-induced NO production in mouse J774A1 cells compound preincubated for 1 hr before LPS treatment by Griess reaction
Inhibition of LPS-induced NO production in mouse J774A1 cells compound preincubated for 1 hr before LPS treatment by Griess reaction
[PMID: 25113933]
J774.A1 IC50
87.22 μM
Compound: 1, Oleanolic acid
Cytotoxicity against mouse J774A1 cells assessed as cell viability by MTT assay relative to control
Cytotoxicity against mouse J774A1 cells assessed as cell viability by MTT assay relative to control
[PMID: 25113933]
Jurkat EC50
> 1 μM
Compound: OA
Antiproliferative activity against human Jurkat cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
Antiproliferative activity against human Jurkat cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
[PMID: 33569941]
K562 EC50
> 100 μM
Compound: OA
Antiproliferative activity against human K562 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
Antiproliferative activity against human K562 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
[PMID: 33569941]
K562 IC50
> 100 μM
Compound: OA
Antiproliferative activity against human K562 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis
Antiproliferative activity against human K562 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis
[PMID: 34352711]
K562 IC50
> 200 μM
Compound: 1; OA
Cytotoxicity against human K562 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human K562 cells assessed as cell growth inhibition after 48 hrs by MTT assay
[PMID: 31673307]
K562 IC50
58.13 μM
Compound: 1, OA
Cytotoxicity against human K562 cells after 72 hrs by MTT assay
Cytotoxicity against human K562 cells after 72 hrs by MTT assay
10.1039/C2MD20051A
K562/Adr IC50
> 200 μM
Compound: 1; OA
Cytotoxicity against human K562/ADR cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human K562/ADR cells assessed as cell growth inhibition after 48 hrs by MTT assay
[PMID: 31673307]
KB IC50
> 10 μM
Compound: OA
Antiproliferative activity against human KB cells incubated for 72 hrs by SRB assay
Antiproliferative activity against human KB cells incubated for 72 hrs by SRB assay
[PMID: 31718182]
KB IC50
> 100 μM
Compound: 11
Cytotoxicity against human KB cells assessed as growth inhibition after 72 hrs by neutral red assay
Cytotoxicity against human KB cells assessed as growth inhibition after 72 hrs by neutral red assay
[PMID: 28318944]
KB CC50
> 500 μM
Compound: 10
Cytotoxic activity in human KB cells by sulforhodamine B assay
Cytotoxic activity in human KB cells by sulforhodamine B assay
[PMID: 29120172]
KB IC50
> 500 μM
Compound: 10
Antiproliferative activity in human KB cells by sulforhodamine B assay
Antiproliferative activity in human KB cells by sulforhodamine B assay
[PMID: 29120172]
L02 IC50
> 200 μM
Compound: 1; OA
Cytotoxicity against human LO2 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human LO2 cells assessed as cell growth inhibition after 48 hrs by MTT assay
[PMID: 31673307]
L5178Y IC50
> 10 μM
Compound: 6
Antiproliferative activity against mouse L5178Y cells after 72 hrs by MTT assay
Antiproliferative activity against mouse L5178Y cells after 72 hrs by MTT assay
[PMID: 30199257]
L5178Y IC50
> 10 μM
Compound: 6
Antiproliferative activity against mouse L5178Y cells harboring human ABCB1 after 72 hrs by MTT assay
Antiproliferative activity against mouse L5178Y cells harboring human ABCB1 after 72 hrs by MTT assay
[PMID: 30199257]
Lewis lung carcinoma cell line IC50
> 150 μM
Compound: 9
Cytotoxicity activity against mouse LLC cells after 48 hrs by MTT assay
Cytotoxicity activity against mouse LLC cells after 48 hrs by MTT assay
[PMID: 19618898]
Lewis lung carcinoma cell line IC50
810.1 μM
Compound: 3; OA
Cytotoxicity activity against mouse LLC cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity activity against mouse LLC cells assessed as cell growth inhibition after 48 hrs by MTT assay
[PMID: 30433783]
LN-229 IC50
> 100 μM
Compound: OA
Antiproliferative activity against human LN-229 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay
Antiproliferative activity against human LN-229 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay
[PMID: 34352711]
Lu1 IC50
> 100 μM
Compound: 11
Cytotoxicity against human Lu1 cells assessed as growth inhibition after 72 hrs by neutral red assay
Cytotoxicity against human Lu1 cells assessed as growth inhibition after 72 hrs by neutral red assay
[PMID: 28318944]
M14 IC50
82 μM
Compound: 5
Cytotoxicity against human M14 cells after 48 hrs by MTT assay
Cytotoxicity against human M14 cells after 48 hrs by MTT assay
[PMID: 21954959]
Macrophage IC50
> 40 μM
Compound: 3
Antiinflammatory activity in mouse macrophages assessed as inhibition of IFN-gamma-induced nitric oxide production after 48 hrs by Griess method
Antiinflammatory activity in mouse macrophages assessed as inhibition of IFN-gamma-induced nitric oxide production after 48 hrs by Griess method
[PMID: 23837912]
Macrophage IC50
18.64 μM
Compound: Oleanolic acid
Anti-osteoclastogensis activity in BALB/c mouse bone marrow macrophage cells assessed as inhibition of RANKL/M-CSF-induced osteoclastogenesis by measuring osteoclasts number incubated for 11 days by TRAP staining based assay
Anti-osteoclastogensis activity in BALB/c mouse bone marrow macrophage cells assessed as inhibition of RANKL/M-CSF-induced osteoclastogenesis by measuring osteoclasts number incubated for 11 days by TRAP staining based assay
[PMID: 36701870]
Macrophage CC50
29.69 μM
Compound: Oleanolic acid
Cytotoxicity against BALB/c mouse bone-marrow derived macrophage cells assessed as reduction in cell viability incubated for 11 days by MTT assay
Cytotoxicity against BALB/c mouse bone-marrow derived macrophage cells assessed as reduction in cell viability incubated for 11 days by MTT assay
[PMID: 36701870]
MCF-12A IC50
> 50 μM
Compound: 1; OA
Cytotoxicity in human MCF12A cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Cytotoxicity in human MCF12A cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
[PMID: 28754470]
MCF7 IC50
> 10 μM
Compound: 16
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
[PMID: 27797185]
MCF7 IC50
> 10 μM
Compound: OA
Antiproliferative activity against human MCF7 cells incubated for 72 hrs by SRB assay
Antiproliferative activity against human MCF7 cells incubated for 72 hrs by SRB assay
[PMID: 31718182]
MCF7 IC50
> 100 μM
Compound: OA
Antiproliferative activity against human MCF7 cells after 48 hrs by CCK-8 assay
Antiproliferative activity against human MCF7 cells after 48 hrs by CCK-8 assay
[PMID: 26343825]
MCF7 IC50
> 100 μM
Compound: 1, Oleanolic acid
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
[PMID: 24487188]
MCF7 GI50
> 100 μM
Compound: 27
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
[PMID: 32345458]
MCF7 IC50
> 100 μM
Compound: 11
Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by neutral red assay
Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by neutral red assay
[PMID: 28318944]
MCF7 IC50
> 150 μM
Compound: OA
Cytotoxicity against human MCF7 cells after 48 hrs by CCK-8 assay
Cytotoxicity against human MCF7 cells after 48 hrs by CCK-8 assay
[PMID: 24422538]
MCF7 IC50
> 150 μM
Compound: 9
Cytotoxic activity against human MCF7 cells after 48 hrs by MTT assay
Cytotoxic activity against human MCF7 cells after 48 hrs by MTT assay
[PMID: 19618898]
MCF7 IC50
> 200 μM
Compound: 1; OA
Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 48 hrs by MTT assay
[PMID: 31673307]
MCF7 EC50
> 30 μM
Compound: OA
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay
[PMID: 31718946]
MCF7 EC50
> 30 μM
Compound: 2
Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
[PMID: 28033541]
MCF7 EC50
> 30 μM
Compound: OA
Cytotoxicity against human MCF7 cells assessed as cell survival after 96 hrs by SRB assay
Cytotoxicity against human MCF7 cells assessed as cell survival after 96 hrs by SRB assay
[PMID: 26177446]
MCF7 EC50
> 30 μM
Compound: OA
Cytotoxicity against human MCF7 cells after 96 hrs by sulforhodamine B assay
Cytotoxicity against human MCF7 cells after 96 hrs by sulforhodamine B assay
[PMID: 30278332]
MCF7 CC50
> 500 μM
Compound: 10
Cytotoxic activity in human MCF7 cells by sulforhodamine B assay
Cytotoxic activity in human MCF7 cells by sulforhodamine B assay
[PMID: 29120172]
MCF7 IC50
> 500 μM
Compound: 10
Antiproliferative activity in human MCF7 cells by sulforhodamine B assay
Antiproliferative activity in human MCF7 cells by sulforhodamine B assay
[PMID: 29120172]
MCF7 IC50
> 60 μM
Compound: OA
Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
[PMID: 24361521]
MCF7 GI50
10.3 μM
Compound: 1; OA
Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
[PMID: 28754470]
MCF7 IC50
12.6 μM
Compound: 1
Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
10.1039/C6MD00061D
MCF7 IC50
12.7 μM
Compound: 1; OA
Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
[PMID: 28754470]
MCF7 IC50
35.4 μM
Compound: 1, OA
Cytotoxicity against human MCF7 cells by MTT assay
Cytotoxicity against human MCF7 cells by MTT assay
[PMID: 23434227]
MCF7 EC50
49.1 μM
Compound: OA
Cytotoxicity against human MCF7 cells after 96 hrs by sulforhodamine-B assay
Cytotoxicity against human MCF7 cells after 96 hrs by sulforhodamine-B assay
[PMID: 29529499]
MCF7 EC50
80 μM
Compound: OA
Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
[PMID: 26750249]
MCF7 EC50
80 μM
Compound: 1; OA
Cytotoxicity against human MCF7 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
[PMID: 27149037]
MDA-MB-231 IC50
> 10 μM
Compound: OA
Antiproliferative activity against human MDA-MB-231 cells incubated for 72 hrs by SRB assay
Antiproliferative activity against human MDA-MB-231 cells incubated for 72 hrs by SRB assay
[PMID: 31718182]
MDA-MB-231 IC50
> 10 μM
Compound: 8
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
[PMID: 30057155]
MDA-MB-231 IC50
> 100 μM
Compound: 1, Oleanolic acid
Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay
[PMID: 24487188]
MDA-MB-231 IC50
> 50 μM
Compound: 1; OA
Cytotoxicity in human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Cytotoxicity in human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
[PMID: 28754470]
MDA-MB-231 CC50
106 μM
Compound: 10
Cytotoxic activity in human MDA-MB-231 cells by sulforhodamine B assay
Cytotoxic activity in human MDA-MB-231 cells by sulforhodamine B assay
[PMID: 29120172]
MDA-MB-231 IC50
134 μM
Compound: 10
Antiproliferative activity in human MDA-MB-231 cells by sulforhodamine B assay
Antiproliferative activity in human MDA-MB-231 cells by sulforhodamine B assay
[PMID: 29120172]
MDA-MB-231 GI50
17.6 μM
Compound: 1; OA
Cytotoxicity in human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
Cytotoxicity in human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
[PMID: 28754470]
MDA-MB-231 IC50
512.4 μM
Compound: 3; OA
Cytotoxicity activity against human MDA-MB-231 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity activity against human MDA-MB-231 cells assessed as cell growth inhibition after 48 hrs by MTT assay
[PMID: 30433783]
MDA-MB-231 IC50
67.87 μM
Compound: 1, OA
Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay
10.1039/C2MD20051A
MDA-MB-435 IC50
> 10 μM
Compound: 8
Cytotoxicity against human MDA-MB-435 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
Cytotoxicity against human MDA-MB-435 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
[PMID: 30057155]
MDA-MB-453 IC50
> 100 μM
Compound: 1, Oleanolic acid
Cytotoxicity against human MDA-MB-453 cells after 48 hrs by MTT assay
Cytotoxicity against human MDA-MB-453 cells after 48 hrs by MTT assay
[PMID: 24487188]
MDA-MB-468 IC50
38.1 μM
Compound: 1; OA
Cytotoxicity in human MDA-MB-468 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Cytotoxicity in human MDA-MB-468 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
[PMID: 28754470]
MDCK CC50
> 100 μM
Compound: OA
Cytotoxicity against dog MDCK cells assessed as reduction in cell viability measured after 40 hrs by Celltiter-Glo assay
Cytotoxicity against dog MDCK cells assessed as reduction in cell viability measured after 40 hrs by Celltiter-Glo assay
[PMID: 31425909]
MDCK CC50
> 100 μM
Compound: OA
Cytotoxicity against MDCK cells assessed as reduction in cell viability by CellTiter-Glo assay
Cytotoxicity against MDCK cells assessed as reduction in cell viability by CellTiter-Glo assay
[PMID: 34795865]
MDCK IC50
> 50 μM
Compound: OA
Antiviral activity against Influenza A virus A/Thailand/Kan353/2004(H5N1) pseudovirus infected in MDCK cells co-infected with HA/HIV assessed as inhibition of viral replication preincubated with virus for 30 mins followed by viral infection for 48 hrs by
Antiviral activity against Influenza A virus A/Thailand/Kan353/2004(H5N1) pseudovirus infected in MDCK cells co-infected with HA/HIV assessed as inhibition of viral replication preincubated with virus for 30 mins followed by viral infection for 48 hrs by
[PMID: 27153348]
MDCK CC50
23.1 μM
Compound: OA
Cytotoxicity against MDCK cells assessed as cell death after 2 days by MTT assay
Cytotoxicity against MDCK cells assessed as cell death after 2 days by MTT assay
[PMID: 27153348]
ME-180 IC50
> 100 μM
Compound: 1, Oleanolic acid
Cytotoxicity against human ME180 cells after 48 hrs by MTT assay
Cytotoxicity against human ME180 cells after 48 hrs by MTT assay
[PMID: 24487188]
MRC5 IC50
> 10 μM
Compound: 6
Cytotoxicity against human MRC5 cells after 24 hrs by MTT assay
Cytotoxicity against human MRC5 cells after 24 hrs by MTT assay
[PMID: 30199257]
NCI/ADR-RES IC50
> 200 μM
Compound: 1; OA
Cytotoxicity against human MCF7/ADR cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human MCF7/ADR cells assessed as cell growth inhibition after 48 hrs by MTT assay
[PMID: 31673307]
NCI-H1975 IC50
> 10 μM
Compound: OA
Antiproliferative activity against human NCI-H1975 cells incubated for 72 hrs by MTS assay
Antiproliferative activity against human NCI-H1975 cells incubated for 72 hrs by MTS assay
[PMID: 31718182]
NCI-H1975 IC50
> 10 μM
Compound: OA
Antiproliferative activity against human NCI-H1975 cells harbouring EGFR L858R/T790M/C797S mutant incubated for 72 hrs by MTS assay
Antiproliferative activity against human NCI-H1975 cells harbouring EGFR L858R/T790M/C797S mutant incubated for 72 hrs by MTS assay
[PMID: 31718182]
NCI-H460 IC50
> 100 μM
Compound: OA
Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay
Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay
[PMID: 34352711]
NCI-N87 IC50
> 10 μM
Compound: 16
Cytotoxicity against human NCI-N87 cells after 72 hrs by MTT assay
Cytotoxicity against human NCI-N87 cells after 72 hrs by MTT assay
[PMID: 27797185]
Neutrophil IC50
0.75 μM
Compound: 15
Inhibition of fMLP/CB-activated human neutrophil degranulation assessed as inhibition of elastase release using MeO-Suc-Ala-Ala-Pro-Val-p-nitroanilide as a substrate after 5 mins
Inhibition of fMLP/CB-activated human neutrophil degranulation assessed as inhibition of elastase release using MeO-Suc-Ala-Ala-Pro-Val-p-nitroanilide as a substrate after 5 mins
[PMID: 21417387]
NIH3T3 IC50
> 10 μM
Compound: 6
Cytotoxicity against mouse NIH/3T3 cells after 24 hrs by MTT assay
Cytotoxicity against mouse NIH/3T3 cells after 24 hrs by MTT assay
[PMID: 30199257]
NIH3T3 EC50
> 30 μM
Compound: OA
Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay
Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay
[PMID: 31718946]
NIH3T3 EC50
> 30 μM
Compound: 2
Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay
Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay
[PMID: 28033541]
NIH3T3 EC50
> 30 μM
Compound: OA
Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by sulforhodamine B assay
Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by sulforhodamine B assay
[PMID: 30278332]
NIH3T3 EC50
57.9 μM
Compound: OA
Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by sulforhodamine-B assay
Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by sulforhodamine-B assay
[PMID: 29529499]
NIH3T3 EC50
76.4 μM
Compound: OA
Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay
Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay
[PMID: 26750249]
NIH3T3 IC50
76.4 μM
Compound: OA
Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay
Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay
[PMID: 24361521]
NIH3T3 EC50
76.4 μM
Compound: 1; OA
Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
[PMID: 27149037]
OVCAR-3 IC50
> 10 μM
Compound: 8
Cytotoxicity against human OVCAR3 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
Cytotoxicity against human OVCAR3 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
[PMID: 30057155]
PANC-1 IC50
362.8 μM
Compound: 3; OA
Cytotoxicity activity against human PANC1 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity activity against human PANC1 cells assessed as cell growth inhibition after 48 hrs by MTT assay
[PMID: 30433783]
PC-3 IC50
> 100 μM
Compound: 1, Oleanolic acid
Cytotoxicity against human PC3 cells after 48 hrs by MTT assay
Cytotoxicity against human PC3 cells after 48 hrs by MTT assay
[PMID: 24487188]
PC-3 IC50
> 30 μM
Compound: 1; OA
Cytotoxicity against human PC3 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human PC3 cells assessed as cell growth inhibition after 48 hrs by MTT assay
[PMID: 29133061]
PC-3 IC50
6.51 μM
Compound: 1, OA
Cytotoxicity against human PC3 cells by MTT assay
Cytotoxicity against human PC3 cells by MTT assay
[PMID: 23434227]
PC-3 IC50
72.74 μM
Compound: 1
Cytotoxicity against human PC3 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
Cytotoxicity against human PC3 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
10.1039/C6MD00061D
Raji IC50
449 nM
Compound: Oleanolic acid
Inhibition of TPA-induced EBV-early antigen activation in human Raji cells assessed as EA activation after 48 hrs
Inhibition of TPA-induced EBV-early antigen activation in human Raji cells assessed as EA activation after 48 hrs
[PMID: 21620532]
RAW264.7 CC50
145.47 μM
Compound: Oleanolic acid
Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
[PMID: 36701870]
RAW264.7 IC50
41.7 μM
Compound: 1, Oleanolic acid
Inhibition of LPS-induced NO production in mouse RAW264.7 cells compound preincubated for 1 hr before LPS treatment by Griess reaction
Inhibition of LPS-induced NO production in mouse RAW264.7 cells compound preincubated for 1 hr before LPS treatment by Griess reaction
[PMID: 25113933]
RAW264.7 IC50
89.12 μM
Compound: 1, Oleanolic acid
Cytotoxicity mouse RAW264.7 cells assessed as cell viability by MTT assay relative to control
Cytotoxicity mouse RAW264.7 cells assessed as cell viability by MTT assay relative to control
[PMID: 25113933]
RAW264.7 IC50
96.63 μM
Compound: Oleanolic acid
Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced IL-1beta level incubated for 48 hrs by ELISA assay
Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced IL-1beta level incubated for 48 hrs by ELISA assay
[PMID: 36701870]
Sf21 IC50
> 40 μM
Compound: 10
Inhibition of human recombinant COX2 expressed in baculovirus infected sf21 cells assessed as decrease in PGE2 formation using arachidonic acid as substrate preincubated for 10 mins followed by substrate addition measured after 45 mins by LC-MS analysis
Inhibition of human recombinant COX2 expressed in baculovirus infected sf21 cells assessed as decrease in PGE2 formation using arachidonic acid as substrate preincubated for 10 mins followed by substrate addition measured after 45 mins by LC-MS analysis
[PMID: 31774676]
Sf9 IC50
> 20 μM
Compound: OA
Inhibition of C-terminal His-tagged/ N-terminal GST-tagged recombinant human EGFR (668 to 1210 residues) expressed in a Baculovirus infected Sf9 cell expression system using poly-EY as substrate incubated for 30 mins by ADP-Glo kinase assay
Inhibition of C-terminal His-tagged/ N-terminal GST-tagged recombinant human EGFR (668 to 1210 residues) expressed in a Baculovirus infected Sf9 cell expression system using poly-EY as substrate incubated for 30 mins by ADP-Glo kinase assay
[PMID: 31718182]
Sf9 IC50
> 20 μM
Compound: OA
Inhibition of C-terminal His-tagged/ N-terminal GST-tagged recombinant human EGFR L858R/T790M double mutant (668 to 1210 residues) expressed in a Baculovirus infected Sf9 cell expression system using poly-EY as substrate incubated for 30 mins by ADP-Glo k
Inhibition of C-terminal His-tagged/ N-terminal GST-tagged recombinant human EGFR L858R/T790M double mutant (668 to 1210 residues) expressed in a Baculovirus infected Sf9 cell expression system using poly-EY as substrate incubated for 30 mins by ADP-Glo k
[PMID: 31718182]
Sf9 IC50
> 20 μM
Compound: OA
Inhibition of C-terminal His-tagged/ N-terminal GST-tagged recombinant human EGFR L858R/T790M/C797S mutant (668 to 1210 residues) expressed in a Baculovirus infected Sf9 cell expression system using poly-EY as substrate incubated for 30 mins by ADP-Glo ki
Inhibition of C-terminal His-tagged/ N-terminal GST-tagged recombinant human EGFR L858R/T790M/C797S mutant (668 to 1210 residues) expressed in a Baculovirus infected Sf9 cell expression system using poly-EY as substrate incubated for 30 mins by ADP-Glo ki
[PMID: 31718182]
SiHa CC50
108.7 μM
Compound: 10
Cytotoxic activity in human SiHa cells by sulforhodamine B assay
Cytotoxic activity in human SiHa cells by sulforhodamine B assay
[PMID: 29120172]
SiHa IC50
110.2 μM
Compound: 10
Antiproliferative activity in human SiHa cells by sulforhodamine B assay
Antiproliferative activity in human SiHa cells by sulforhodamine B assay
[PMID: 29120172]
T47D IC50
36.22 μM
Compound: 1; OA
Cytotoxicity in human T47D cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Cytotoxicity in human T47D cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
[PMID: 28754470]
U-87MG ATCC IC50
18.52 μM
Compound: OA
Cytotoxicity against human U87MG cells assessed as cell viability after 72 hrs by MTT assay
Cytotoxicity against human U87MG cells assessed as cell viability after 72 hrs by MTT assay
[PMID: 23992864]
Vero CC50
> 500 μM
Compound: 10
Cytotoxic activity in African green monkey Vero cells by sulforhodamine B assay
Cytotoxic activity in African green monkey Vero cells by sulforhodamine B assay
[PMID: 29120172]
Vero IC50
> 500 μM
Compound: 10
Antiproliferative activity in African green monkey Vero cells by sulforhodamine B assay
Antiproliferative activity in African green monkey Vero cells by sulforhodamine B assay
[PMID: 29120172]
WI-38 IC50
14.5 μM
Compound: 10
Cytotoxicity against human WI 38 cells after 48 hrs by WST-8 assay
Cytotoxicity against human WI 38 cells after 48 hrs by WST-8 assay
[PMID: 15730243]
WI-38 VA13 IC50
123 μM
Compound: 10
Cytotoxicity against human VA13 cells after 48 hrs by WST-8 assay
Cytotoxicity against human VA13 cells after 48 hrs by WST-8 assay
[PMID: 15730243]
Z-138 IC50
> 100 μM
Compound: OA
Antiproliferative activity against human Z138 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis
Antiproliferative activity against human Z138 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis
[PMID: 34352711]
In Vitro

Oleanolic acid (OA) suppresses the proliferation of lung cancer cells in both dose- and time-dependent manners, along with an increase in miR-122 abundance. CCNG1 and MEF2D, two putative miR-122 targets, are found to be downregulated by OA treatment [1]. OA induces autophagy in normal tissue-derived cells without cytotoxicity. OA-induced autophagy is shown to decrease the proliferation of KRAS-transformed normal cells and to impair their invasion and anchorage-independent growth[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Mouse model experiments also demonstrat that OA suppresses the growth of KRAS-transformed breast epithelial cell MCF10A-derived tumor xenograft by inducing autophagy [2]. Activation of MAPK pathways, including p-38 MAPK, JNK and ERK, is triggered by OA in both a dose and time-dependent fashion in all the tested cancer cells. OA induces p38 MAPK activation promoted mitochondrial translocation of Bax and Bim, and inhibits Bcl-2 function by enhancing their phosphorylation. OA can induce reactive oxygen species (ROS)-dependent ASK1 activation, and this event is indispensable for p38 MAPK-dependent apoptosis in cancer cells[3].It is also proved that p38 MAPK knockdown A549 tumors are resistant to the growth-inhibitory effect of OA[3]. In OA-treated EAM mice the number of Treg cells and the production of IL-10 and IL-35 are markedly increased, while proinflammatory and profibrotic cytokines are significantly reduced[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial
Molecular Weight

456.70

Formula

C30H48O3

CAS No.
Appearance

Solid

Color

White to off-white

SMILES

C[C@]([C@@]1([H])[C@]2(CC[C@@H]3O)C)(CC[C@@]2([H])C3(C)C)[C@@](C4=CC1)(CC[C@]5(C(O)=O)[C@@]4([H])CC(C)(C)CC5)C

Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.

Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
Solvent & Solubility
In Vitro: 

DMF : 45.45 mg/mL (99.52 mM; ultrasonic and warming and heat to 60°C)

DMSO : 5 mg/mL (10.95 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.1896 mL 10.9481 mL 21.8962 mL
5 mM 0.4379 mL 2.1896 mL 4.3792 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: 0.5 mg/mL (1.09 mM); Suspended solution; Need ultrasonic

    This protocol yields a suspended solution of 0.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (5.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: 0.5 mg/mL (1.09 mM); Suspended solution; Need ultrasonic

    This protocol yields a suspended solution of 0.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (5.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: ≥98.0%

References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO / DMF 1 mM 2.1896 mL 10.9481 mL 21.8962 mL 54.7405 mL
5 mM 0.4379 mL 2.1896 mL 4.3792 mL 10.9481 mL
10 mM 0.2190 mL 1.0948 mL 2.1896 mL 5.4741 mL
DMF 15 mM 0.1460 mL 0.7299 mL 1.4597 mL 3.6494 mL
20 mM 0.1095 mL 0.5474 mL 1.0948 mL 2.7370 mL
25 mM 0.0876 mL 0.4379 mL 0.8758 mL 2.1896 mL
30 mM 0.0730 mL 0.3649 mL 0.7299 mL 1.8247 mL
40 mM 0.0547 mL 0.2737 mL 0.5474 mL 1.3685 mL
50 mM 0.0438 mL 0.2190 mL 0.4379 mL 1.0948 mL
60 mM 0.0365 mL 0.1825 mL 0.3649 mL 0.9123 mL
80 mM 0.0274 mL 0.1369 mL 0.2737 mL 0.6843 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Oleanolic acid
Cat. No.:
HY-N0156
Quantity:
MCE Japan Authorized Agent: